| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Net Income | -5.54 | -0.35 |
| Diluted EPS | -0.49 | -0.58 |
- Net Income YoY
- -1,479.2%
Key highlights
- Net loss expanded to $5.54 million for Q3 2026, compared to $0.35 million in the prior-year period
- Year-over-year net income growth declined by 1,479.2% as clinical activities intensified
- Diluted earnings per share (EPS) improved slightly to a loss of $0.49 from a loss of $0.58 in Q3 2025
- Company identified as a going concern with a substantial need for additional capital to maintain its Nasdaq listing
- Primary focus remains on exaluren for the treatment of Alport Syndrome and ADPKD
How the Period Went
During the third quarter of 2026, Eloxx Pharmaceuticals reported a significant deepening of its bottom-line deficit. The company recorded a net loss of $5.54 million, representing a sharp 1,479.2% decline compared to the $0.35 million loss reported in the third quarter of 2025. Despite this wider net loss, the diluted earnings per share (EPS) showed a slight nominal improvement, moving from a loss of $0.58 per share in the prior-year period to a loss of $0.49 per share in Q3 2026. This disconnect between net income and EPS reflects shifts in the company's share structure during the intervening twelve months.
Margins and Profitability
- The company reported a net loss of $5.54 million in Q3 2026, a significant increase from the $0.35 million loss in Q3 2025.
- Operating expenses are primarily driven by clinical development costs for the lead candidate, exaluren.
- Management has indicated that existing cash reserves necessitate additional funding to continue as a going concern.
- The current financial trajectory reflects the high-burn rate typical of clinical-stage biotechnology firms without commercial revenue.
Business Overview
Eloxx Pharmaceuticals is a clinical-stage biotechnology company centered on the development of novel RNA-modulating therapeutics. Its primary focus is exaluren (ELX-02), a small molecule designed to promote the translation of proteins in patients with nonsense mutations. The company is currently targeting rare and orphan diseases, specifically Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease (ADPKD). As an organization without recurring revenue, its operations are dedicated to advancing these candidates through clinical trials, navigating complex regulatory pathways, and establishing the foundational data necessary for potential commercialization or strategic partnerships.
Financial Context
The financial performance of Eloxx Pharmaceuticals reflects the high-capital nature of the biotechnology sector. While the company's P/E ratio sits at 3.74, this figure is often volatile for clinical-stage firms undergoing significant cash burn. Market sentiment has been cautious, with the stock price of $13.15 reflecting a 28.02% decline over the last quarter. However, recent technical indicators suggest stabilization, as the Relative Strength Index (RSI) currently sits at 47.2, placing it in neutral territory. With a market capitalization of approximately $53.74 million, Eloxx remains a micro-cap player navigating the funding challenges typical of the healthcare sector.
Down 3.0% since our story on 16 Nov: $13.15 when we broke it → $12.75 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $12.50 |
|---|---|
| 20 Oct | $13.22 |
| 21 Oct | $13.30 |
| 22 Oct | $13.12 |
| 23 Oct | $12.80 |
| 26 Oct | $13.17 |
| 27 Oct | $13.34 |
| 28 Oct | $13.12 |
| 29 Oct | $13.20 |
| 30 Oct | $13.45 |
| 2 Nov | $12.84 |
| 3 Nov | $12.92 |
| 4 Nov | $12.74 |
| 5 Nov | $12.80 |
| 6 Nov | $12.44 |
| 9 Nov | $13.51 |
| 10 Nov | $12.90 |
| 11 Nov | $13.01 |
| 12 Nov | $12.89 |
| 13 Nov | $13.15 |
| 16 Nov | $12.75 |
Industry Landscape
The biotechnology industry continues to face a bifurcated environment where clinical-stage companies must compete for limited venture and public equity capital. Peers in the rare kidney disease space are similarly focused on specialized orphan drug designations, which offer potential market exclusivity but require rigorous data proof-points. Demand for Alport Syndrome and ADPKD treatments remains high due to a lack of approved therapies, creating a favorable regulatory tailwind for companies that can prove efficacy. However, the sector remains sensitive to interest rate environments and general risk-off sentiment, making liquidity management as critical as clinical success.
| Share price | $13.15 |
|---|---|
| Market cap | $54M |
| P/E (TTM) | 3.7× |
| 1-month price change | +7.70% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Eloxx Pharmaceuticals, Inc. announcing Q3 2026 financial results.
Track Eloxx Pharmaceuticals, Inc. live
Get the next Eloxx Pharmaceuticals, Inc. SEC filing seconds after it lands.



